Oliceridine - Trevena

Drug Profile

Oliceridine - Trevena

Alternative Names: OLINVO; TRV 130A; TRV-130

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trevena
  • Class Analgesics; Pyridines; Small molecules; Spiro compounds; Thiophenes
  • Mechanism of Action Beta arrestin inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Postoperative pain
  • Phase II Pain

Most Recent Events

  • 02 Aug 2018 Trevena intends to launch Oliceridine in USA in the first half of 2019
  • 01 May 2018 Oliceridine licensed to Jiangsu Nhwa Pharmaceutical in China
  • 27 Apr 2018 Oliceridine licensed to Pharmbio Korea in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top